Importantly, this rosiglitazone effect was macrophage-PPARγ-dependent because tumor cell proliferation was increased equally when co-cultured with PPARγ-deficient macrophages regardless of rosiglitazone or vehicle treatment (Figure 2I). This evidence concerns the gene PPARG and neoplasm.